B+L initiates Phase III program for glaucoma drug candidate licensed from Nicox

Article

Bausch + Lomb has started its Phase III clinical program of latanoprostene bunod licensed by Nicox S.A. to B+L. B+L’s drug candidate is meant to reduce IOP in patients with elevated IOP due to glaucoma or ocular hypertension.

Sophia Antipolis, France and Madison, NJ-Bausch + Lomb (B+L) has initiated its Phase III clinical program of latanoprostene bunod (previously known as BOL-303259-X and NCX 116) licensed by Nicox S.A. to B+L.

B+L’s drug candidate is intended for the reduction of intraocular pressure (IOP) in patients with elevated IOP due to glaucoma or ocular hypertension. Latanoprostene bunod is a nitric oxide-donating prostaglandin F2-alpha analog.

This pivotal Phase III program includes two separate randomized, multicenter, double-masked, parallel-group clinical studies, APOLLO and LUNAR, designed to compare the efficacy and safety of latanoprostene bunod administered QD with timolol maleate 0.5% administered BID in lowering IOP in patients with open-angle glaucoma or ocular hypertension.

The primary endpoint of both studies, which will include a combined total of approximately 800 patients, is the reduction in mean IOP measured at specified time points during three months of treatment. The Phase III studies are pivotal for U.S. registration and will be conducted in North America and Europe.

Additional information about the studies can be found at www.clinicaltrials.gov.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.